Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

Robert Motzer, Boris Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María J. Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso KimHoward Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo de Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri

Research output: Contribution to journal › Article › peer-review

603 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science